Soaring process development revenues prompt Avid to raise full-year guidance 15-Dec-2022 By Nick Taylor Avid Bioservices has raised its full-year revenue guidance after process development sales hit a new high in its latest quarterly financial results.
Avid frames Halozyme setback as potential positive for CDMO business 19-Dec-2019 By Nick Taylor Avid Bioservices sees potential upside to clinical development setback at big customer Halozyme.
Avid inks new, expanded contract manufacturing agreements 09-Jul-2019 By Melissa Fassbender A top ten global pharmaceutical company has contracted the biologics CDMO, which also has expanded a relationship with an existing biotech customer.